In my February 13, 2026 post I state that West Pharmaceutical (WST) is the silent winner of the GLP-1 obesity drug boom. Novo Nordisk (NVO) and Eli Lilly (LLY) may grab the headlines. WST, however, is the 'picks and shovels' play in this space. I initiated a 100 share position in a 'Core' account in [...]
I last reviewed RTX Corporation (RTX) in this January 27, 2026 post following the release of its Q4 and FY2025 results. With the release of Q1 2026 results on April 21, I revisit this existing holding. Business Overview RTX has 3 business segments (Collins Aerospace, Pratt & Whitney, and Raytheon). Investors unfamiliar with RTX [...]
Following the release of Danaher's (DHR) FY2025 results on January 28, 2026 and my February 1, 2026 post, DHR announced that it had entered into a definitive agreement to acquire Masimo Corporation (MASI) for $180/share in cash, or a total enterprise value of ~$9.9B including assumed indebtedness and net of acquired cash. This represents [...]
I have been away the majority of March and the first half of April thus the delay in providing this FFJ Portfolio – March 2026 report. All previous monthly reports are accessible here. Market conditions in March presented an opportunity for long-term investors to acquire shares in great companies at favorable valuations. During the month, [...]
I last analyzed Paycom Software, Inc. (PAYC) in my November 7, 2025 post at which time the Q3 and YTD2025 results were the most recent. Although the Q4 and FY2025 results were released on February 11, the Form 10-K was only made available shortly before I departed on a ski vacation. Although my ~$227.0705 average [...]
I last reviewed Paychex (PAYX) in this November 5, 2025 post at which time the most current financial information was for Q1 2026. At the time, shares were trading at ~$115.77. As luck would have it, PAYX continues to generate strong results but the share price as I compose this post on March 26, 2026 [...]
In my November 21, 2025 post I reviewed Veeva (VEEV) following the release of its Q3 and YTD2026 results. I subsequently provided updates on January 6 and January 18, 2026 that are accessible through the FFJ Archives. The Q4 and FY2026 results are now available thus prompting me to revisit this existing holding. Business [...]
In my December 20, 2025 post I look at Cintas' (CTAS) Q2 and YTD2026 results. I also reference my December 8, 2025 post in which I raise the question of whether CTAS could take another run at trying to acquire Unifirst (UNF) - its largest US competitor. On December 22, 2025, CTAS disclosed its proposal [...]
When I reviewed CME Group (CME) in my October 25, 2025 post, it had recently released its Q3 and YTD2025 results. In that post I express my optimism that CME will start repurchasing shares. Given this optimism I purchased an additional 100 shares @ $266.875 on January 6, 2026 in a ‘Core’ account in [...]
My last Accenture (ACN) review is in this December 19, 2025 post. With the release of Q2 and YTD2026 results and updated FY2026 guidance on March 19, I revisit this existing holding. Business Overview I reference my prior post in which I provide a very high level overview. The best way to learn about ACN, [...]
